Can Hong Kong PGT Screen for Genetic Diseases? Technical Boundaries and Clinical Applications
Hong Kong PGT (Preimplantation Genetic Testing) can screen for specific genetic diseases, including monogenic disorders and chromosomal structural abnormalities, but not all genetic conditions. PGT-M targets known pathogenic gene mutations, PGT-A screens for aneuploidy, and PGT-SR is for carriers of chromosomal structural rearrangements. Genetic counseling and pedigree validation are required before embryo testing. Suitability depends on medical indications, defined genetic mutations, and platform availability.
Main content begins
Direct Answer
Hong Kong PGT technology can screen for genetic diseases, but not all genetic conditions are within its detection scope.
PGT (Preimplantation Genetic Testing) primarily covers three categories: monogenic diseases (PGT-M), chromosomal aneuploidy (PGT-A), and chromosomal structural abnormalities (PGT-SR).
Whether genetic screening is suitable depends on whether the pathogenic gene is identified, the availability of testing platforms, and the presence of clear medical indications.
Why Focus on Genetic Disease Screening? A Reproductive Medicine Perspective
Genetic diseases are a major cause of early miscarriage, fetal malformations, neonatal death, and severe childhood illnesses. In assisted reproduction, Preimplantation Genetic Testing (PGT) offers a means to identify genetic risks before embryo transfer. Unlike prenatal diagnosis (amniocentesis, chorionic villus sampling), PGT is performed at the embryo stage, potentially avoiding recurrent miscarriages or pregnancy terminations due to genetic issues.
Hong Kong's PGT technology developed early, with laboratory standards aligned internationally and a relatively comprehensive genetic counseling system. However, it is crucial to understand: PGT is not a "universal filter"; it has strict technical boundaries and applicable conditions.
Three Technical Pathways for Genetic Disease Screening via Hong Kong PGT
PGT technology is divided into three subcategories based on the testing target, each with distinct applications and detection scopes:
| Technology Type | Testing Target | Example Applicable Diseases | Key Limitations |
|---|---|---|---|
| PGT‑M Monogenic Disease Testing |
Mutation sites of known pathogenic genes | Thalassemia, Spinal Muscular Atrophy (SMA), Huntington's disease, Cystic fibrosis, Hereditary deafness, Marfan syndrome, BRCA1/2 related hereditary tumor syndromes | Pathogenic gene and mutation site must be identified; requires pedigree validation; cannot detect unknown genes or de novo mutations |
| PGT‑A Aneuploidy Screening |
Chromosomal numerical abnormalities (23 pairs) | Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), sex chromosome aneuploidies, etc. | Cannot detect monogenic diseases; cannot detect microdeletions/microduplications (requires separate microarray) |
| PGT‑SR Structural Rearrangement Testing |
Chromosomal structural abnormalities (translocations, inversions, deletions, duplications) | Balanced translocation, Robertsonian translocation, chromosomal inversion carriers | Requires identification of chromosomal breakpoints; some complex rearrangements may not be precisely detected |
Core Conclusion: For genetic disease screening via Hong Kong PGT, PGT‑M is the primary technology. PGT‑A and PGT‑SR address chromosomal issues, not traditional "genetic disease screening".
Key Differences Between Hong Kong and Mainland China in This Field
Many patients are curious about the differences between Hong Kong and the mainland regarding this technology. From a clinical practice perspective, several dimensions show notable differences:
- Genetic Counseling System: In Hong Kong, genetic counseling is led by clinical geneticists or genetic counselors, with more standardized procedures and typically longer consultation times. Mainland China has uneven distribution of genetic counseling resources, with some centers relying on reproductive doctors.
- Testing Platform Options: Hong Kong has access to a more diverse range of genetic testing platforms (including European and American laboratories), potentially offering more flexible testing solutions for rare mutations or complex pedigrees.
- Embryo Biopsy Technique: Hong Kong commonly uses blastocyst-stage biopsy (Day 5/6), obtaining more cells for higher accuracy. Some mainland centers still use cleavage-stage biopsy.
- Legal and Ethical Framework: Hong Kong has stricter approval for PGT indications, requiring pedigree validation reports and genetic counseling records. Mainland approval processes vary by center.
- Overall Cycle Duration: In Hong Kong, from initial genetic counseling to obtaining transferable embryos typically takes 4-6 months, with pedigree validation taking 1-3 months. Some mainland centers may have faster processes, but quality assessment is necessary.
Five Most Easily Overlooked Details
In clinical consultations, the following issues are often overlooked by patients but significantly impact test results and subsequent decisions:
- Pedigree validation must be completed before embryo testing. Without prior genetic mutation validation in carrier parents (or proband), embryo test results cannot be accurately interpreted. Pedigree validation requires a blood draw and typically takes 2-6 weeks.
- Testing scope does not equal disease coverage. PGT‑M can only detect known specific mutations, not all possible mutations on the same gene. For example, thalassemia has hundreds of mutation subtypes; testing protocols target only the identified familial mutation.
- Embryo mosaicism can affect result interpretation. About 5%-10% of embryos are mosaic (mixed normal and abnormal cells), and biopsy cells may not fully represent the entire embryo. This is an inherent limitation of PGT.
- Prenatal diagnosis is still recommended after testing. PGT is a screening technology, not diagnostic. For embryos deemed "normal" by PGT‑M, amniocentesis for prenatal confirmation is still advised after pregnancy.
- Genetic counseling is not just a "formality". Genetic counseling involves collecting three-generation family history, assessing inheritance patterns, calculating recurrence risks, and explaining test limitations and possible result types (including variants of uncertain significance).
Four Most Common Misconceptions to Avoid
| Misconception | Fact |
|---|---|
| "PGT can screen for all genetic diseases" | It can only screen for known monogenic diseases with identified pathogenic genes and chromosomal numerical/structural abnormalities. Polygenic diseases (e.g., diabetes, hypertension, schizophrenia) are not within scope. |
| "A normal screening result guarantees a healthy embryo" | PGT cannot detect all genetic issues (e.g., de novo mutations, mitochondrial diseases, imprinting disorders), and technical errors exist. A normal result ≠ 100% no genetic risk. |
| "Hong Kong can screen for any genetic disease" | Whether PGT‑M is available for a specific disease depends on whether the local laboratory has developed a corresponding testing protocol. Rare diseases may lack available testing platforms. |
| "Pedigree validation is unnecessary; direct embryo testing is fine" | Without pedigree validation, PGT‑M results are unreliable, unable to distinguish between healthy carriers and non-carriers, nor rule out testing errors. |
From Genetic Counseling to Embryo Transfer: Standard Process
The complete process for genetic disease screening via Hong Kong PGT generally includes the following stages:
- Initial Consultation and Genetic Counseling (1-2 visits): Collection of family history, reproductive history, and relevant medical records. Genetic counselor assesses risk, determines need for PGT and appropriate technology type.
- Pedigree Validation (1-3 months): Peripheral blood draw from patient, partner, and relevant family members (e.g., proband, parents) for genetic testing or karyotyping to identify pathogenic mutation or structural abnormality.
- Testing Protocol Design and Informed Consent: Based on validation results, the laboratory designs a personalized embryo testing protocol. Patient learns about scope, limitations, expected result types, and subsequent decision options.
- Ovarian Stimulation and Egg Retrieval (approx. 2-3 weeks): Standard IVF process: stimulation, egg retrieval, fertilization.
- Embryo Culture and Biopsy (5-7 days): Embryos cultured to blastocyst stage; embryologist creates opening in zona pellucida and removes 3-5 trophectoderm cells for genetic analysis.
- Genetic Testing and Result Interpretation (2-4 weeks): Biopsied cells undergo amplification and genetic analysis. Report interpreted by laboratory geneticist and clinical geneticist.
- Genetic Counseling and Embryo Selection: Doctor/genetic counselor explains results, categorizing embryos as "transferable", "non-transferable", or "of uncertain significance".
- Frozen Embryo Transfer and Prenatal Follow-up: Selected embryo transferred. Prenatal diagnosis (amniocentesis) recommended after pregnancy confirmation.
Timeline Reference
- Pedigree validation: 1-3 months (depends on mutation type and lab schedule)
- Stimulation + retrieval + culture: approx. 3-4 weeks
- Embryo testing + result interpretation: 2-4 weeks
- From initiation to transferable embryo: typically 4-6 months
Frequently Asked Questions
No. Three conditions must be met: ① Pathogenic gene identified; ② Mutation site known; ③ Testing protocol available. Some rare diseases or de novo mutations may not be detectable.
No. PGT‑A only screens for chromosomal numerical abnormalities, not single-gene mutations. If a monogenic disease runs in the family, PGT‑M or combined testing is needed.
Depends on the inheritance pattern, patient age, and ovarian function. For autosomal dominant diseases, theoretically 50% of embryos may carry the mutation; for autosomal recessive, 25%. Combined with aneuploidy risk, the actual number varies individually.
Costs vary by hospital, testing platform, and number of diseases tested. Approximate ranges: PGT‑M per family HKD 80,000-150,000 (including counseling, pedigree validation, embryo testing); PGT‑A per embryo HKD 3,000-6,000; total cycle cost (including IVF) typically HKD 150,000-250,000. Please confirm with the hospital.
① Polygenic diseases (e.g., schizophrenia, type 2 diabetes); ② Diseases with unclear inheritance patterns; ③ Insufficient embryo numbers (e.g., very low ovarian reserve); ④ Patient or partner with severe psychological issues unable to handle result uncertainty.
Practitioner's Observation: On Choices and Decisions
With over a decade in reproductive medicine, I have seen many families hold overly high expectations for PGT genetic disease screening. PGT is a valuable tool, but it is not a panacea.
One easily overlooked fact is: PGT's success is built on thorough genetic counseling and pedigree validation. Skipping these steps significantly compromises result reliability. Additionally, for older women, PGT‑A can reduce miscarriage rates due to aneuploidy but does not improve live birth rates—patients need realistic expectations.
Hong Kong's healthcare system offers advantages in genetic counseling and lab quality control, but patients must make comprehensive decisions based on their own circumstances (age, ovarian function, genetic disease type, financial situation).
Doctor's Advice:
If you are considering Hong Kong PGT for genetic disease screening, it is recommended to complete the following three steps first:
① Gather a detailed family genetic history (at least three generations);
② Undergo risk assessment at a formal genetic counseling clinic;
③ Confirm whether the pathogenic gene is identified and whether a testing platform is available in Hong Kong.
Do not blindly pursue "PGT"; first confirm whether you truly need it and which technology type best suits your situation.
Risk Reminder: Preimplantation genetic testing is a specialized technology in assisted reproduction, carrying inherent risks such as false positives, false negatives, and undetected mosaicism. All results must be interpreted comprehensively by genetic counselors and clinicians. Standard prenatal diagnosis is still recommended after pregnancy. This content is for medical knowledge reference only and does not constitute medical advice.
0 comments